Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells

Se Jin Oh, Kyung Hee Noh, Young Ho Lee, Soon Oh Hong, Kwon Ho Song, Hyo Jung Lee, Soyeon Kim, Tae Min Kim, Ju Hong Jeon, Jae Hong Seo, Dong Wan Kim, Tae Woo Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The fusion between anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) is a causative factor in a unique subset of patients with non-small cell lung carcinoma (NSCLC). Although the inhibitor crizotinib, as it blocks the kinase activity of the resulting EML4-ALK fusion protein, displays remarkable initial responses, a fraction of NSCLC cases eventually become resistant to crizotinib by acquiring mutations in the ALK domain or activating bypass pathways via EGFR, KIT, or KRAS. Cancer stem cell (CSC) theory provides a plausible explanation for acquisition of tumorigenesis and resistance. However, the question as to whether EML4-ALK-driven tumorigenesis is linked with the stem-like property and whether the stemness is an effective target in controlling EML4-ALK+ NSCLC including crizotinib-resistant NSCLC cells has not been addressed. Here, we report that stemlike properties stem from ALK activity in EML4-ALK+ NSCLC cells. Notably, treatment with rapamycin, a CSC targeting agent, attenuates stem-like phenotypes of the EML4- ALK+ cells, which increased capability of tumor formation and higher expression of stemness-associated molecules such as ALDH, NANOG, and OCT4. Importantly, combinational treatment with rapamycin and crizotinib leads to synergistic anti-tumor effects on EML4-ALK+ NSCLC cells as well as on those resistant to crizotinib. Thus, we provide a proof of principle that targeting stemness would be a novel strategy to control intractable EML4-ALK+ NSCLC.

Original languageEnglish
Pages (from-to)40255-40267
Number of pages13
JournalOncotarget
Volume6
Issue number37
DOIs
Publication statusPublished - 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplastic Stem Cells
Sirolimus
Carcinogenesis
MAP4
anaplastic lymphoma kinase
Neoplasms
Phosphotransferases
crizotinib
Phenotype
Mutation
Therapeutics

Keywords

  • EML4-ALK
  • NSCLC
  • Rapamycin
  • Resistance
  • Stemness factor

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. / Oh, Se Jin; Noh, Kyung Hee; Lee, Young Ho; Hong, Soon Oh; Song, Kwon Ho; Lee, Hyo Jung; Kim, Soyeon; Kim, Tae Min; Jeon, Ju Hong; Seo, Jae Hong; Kim, Dong Wan; Kim, Tae Woo.

In: Oncotarget, Vol. 6, No. 37, 2015, p. 40255-40267.

Research output: Contribution to journalArticle

Oh, SJ, Noh, KH, Lee, YH, Hong, SO, Song, KH, Lee, HJ, Kim, S, Kim, TM, Jeon, JH, Seo, JH, Kim, DW & Kim, TW 2015, 'Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells', Oncotarget, vol. 6, no. 37, pp. 40255-40267. https://doi.org/10.18632/oncotarget.5434
Oh, Se Jin ; Noh, Kyung Hee ; Lee, Young Ho ; Hong, Soon Oh ; Song, Kwon Ho ; Lee, Hyo Jung ; Kim, Soyeon ; Kim, Tae Min ; Jeon, Ju Hong ; Seo, Jae Hong ; Kim, Dong Wan ; Kim, Tae Woo. / Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. In: Oncotarget. 2015 ; Vol. 6, No. 37. pp. 40255-40267.
@article{2c44798aea704efca8d0e4a4628f2b6f,
title = "Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells",
abstract = "The fusion between anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) is a causative factor in a unique subset of patients with non-small cell lung carcinoma (NSCLC). Although the inhibitor crizotinib, as it blocks the kinase activity of the resulting EML4-ALK fusion protein, displays remarkable initial responses, a fraction of NSCLC cases eventually become resistant to crizotinib by acquiring mutations in the ALK domain or activating bypass pathways via EGFR, KIT, or KRAS. Cancer stem cell (CSC) theory provides a plausible explanation for acquisition of tumorigenesis and resistance. However, the question as to whether EML4-ALK-driven tumorigenesis is linked with the stem-like property and whether the stemness is an effective target in controlling EML4-ALK+ NSCLC including crizotinib-resistant NSCLC cells has not been addressed. Here, we report that stemlike properties stem from ALK activity in EML4-ALK+ NSCLC cells. Notably, treatment with rapamycin, a CSC targeting agent, attenuates stem-like phenotypes of the EML4- ALK+ cells, which increased capability of tumor formation and higher expression of stemness-associated molecules such as ALDH, NANOG, and OCT4. Importantly, combinational treatment with rapamycin and crizotinib leads to synergistic anti-tumor effects on EML4-ALK+ NSCLC cells as well as on those resistant to crizotinib. Thus, we provide a proof of principle that targeting stemness would be a novel strategy to control intractable EML4-ALK+ NSCLC.",
keywords = "EML4-ALK, NSCLC, Rapamycin, Resistance, Stemness factor",
author = "Oh, {Se Jin} and Noh, {Kyung Hee} and Lee, {Young Ho} and Hong, {Soon Oh} and Song, {Kwon Ho} and Lee, {Hyo Jung} and Soyeon Kim and Kim, {Tae Min} and Jeon, {Ju Hong} and Seo, {Jae Hong} and Kim, {Dong Wan} and Kim, {Tae Woo}",
year = "2015",
doi = "10.18632/oncotarget.5434",
language = "English",
volume = "6",
pages = "40255--40267",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "37",

}

TY - JOUR

T1 - Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells

AU - Oh, Se Jin

AU - Noh, Kyung Hee

AU - Lee, Young Ho

AU - Hong, Soon Oh

AU - Song, Kwon Ho

AU - Lee, Hyo Jung

AU - Kim, Soyeon

AU - Kim, Tae Min

AU - Jeon, Ju Hong

AU - Seo, Jae Hong

AU - Kim, Dong Wan

AU - Kim, Tae Woo

PY - 2015

Y1 - 2015

N2 - The fusion between anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) is a causative factor in a unique subset of patients with non-small cell lung carcinoma (NSCLC). Although the inhibitor crizotinib, as it blocks the kinase activity of the resulting EML4-ALK fusion protein, displays remarkable initial responses, a fraction of NSCLC cases eventually become resistant to crizotinib by acquiring mutations in the ALK domain or activating bypass pathways via EGFR, KIT, or KRAS. Cancer stem cell (CSC) theory provides a plausible explanation for acquisition of tumorigenesis and resistance. However, the question as to whether EML4-ALK-driven tumorigenesis is linked with the stem-like property and whether the stemness is an effective target in controlling EML4-ALK+ NSCLC including crizotinib-resistant NSCLC cells has not been addressed. Here, we report that stemlike properties stem from ALK activity in EML4-ALK+ NSCLC cells. Notably, treatment with rapamycin, a CSC targeting agent, attenuates stem-like phenotypes of the EML4- ALK+ cells, which increased capability of tumor formation and higher expression of stemness-associated molecules such as ALDH, NANOG, and OCT4. Importantly, combinational treatment with rapamycin and crizotinib leads to synergistic anti-tumor effects on EML4-ALK+ NSCLC cells as well as on those resistant to crizotinib. Thus, we provide a proof of principle that targeting stemness would be a novel strategy to control intractable EML4-ALK+ NSCLC.

AB - The fusion between anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) is a causative factor in a unique subset of patients with non-small cell lung carcinoma (NSCLC). Although the inhibitor crizotinib, as it blocks the kinase activity of the resulting EML4-ALK fusion protein, displays remarkable initial responses, a fraction of NSCLC cases eventually become resistant to crizotinib by acquiring mutations in the ALK domain or activating bypass pathways via EGFR, KIT, or KRAS. Cancer stem cell (CSC) theory provides a plausible explanation for acquisition of tumorigenesis and resistance. However, the question as to whether EML4-ALK-driven tumorigenesis is linked with the stem-like property and whether the stemness is an effective target in controlling EML4-ALK+ NSCLC including crizotinib-resistant NSCLC cells has not been addressed. Here, we report that stemlike properties stem from ALK activity in EML4-ALK+ NSCLC cells. Notably, treatment with rapamycin, a CSC targeting agent, attenuates stem-like phenotypes of the EML4- ALK+ cells, which increased capability of tumor formation and higher expression of stemness-associated molecules such as ALDH, NANOG, and OCT4. Importantly, combinational treatment with rapamycin and crizotinib leads to synergistic anti-tumor effects on EML4-ALK+ NSCLC cells as well as on those resistant to crizotinib. Thus, we provide a proof of principle that targeting stemness would be a novel strategy to control intractable EML4-ALK+ NSCLC.

KW - EML4-ALK

KW - NSCLC

KW - Rapamycin

KW - Resistance

KW - Stemness factor

UR - http://www.scopus.com/inward/record.url?scp=84950129922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950129922&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5434

DO - 10.18632/oncotarget.5434

M3 - Article

VL - 6

SP - 40255

EP - 40267

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -